genetron holdings limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. the company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as hccscreen, a proprietary assay for the early screening of liver cancer. it also provides in-vitro diagnostics products, including 8-gene lung cancer assay, an ivd assay product based on semiconductor sequencing to detect lung cancer; genetron 3d biochip reading instrument; idh1/tert gene assays for glioma; genetron s5, a semiconductor sequencer used in the field of gene detection; and genetron s2000 that enables gene panel sequencing. in addition, the company develops ctdna lung cancer assay for mutations in the epidermal growth factor receptor gene. it also offers development services in the areas of genomics research and clinical development in collabor
Company profile
Ticker
GTH
Exchange
Website
CEO
Si Zhen Wang
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
GTH stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
8 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Mar 24
25-NSE
Exchange delisting
28 Mar 24
SC 13E3/A
Going private transaction (amended)
28 Mar 24
6-K
Genetron Health Announces Completion of Going Private Transaction
28 Mar 24
6-K
Genetron Health Announces Shareholders’ Approval of Merger Agreement
21 Feb 24
SC 13E3/A
Going private transaction (amended)
17 Jan 24
6-K
Genetron Health to Hold Extraordinary General Meeting of Shareholders
17 Jan 24
SC 13E3/A
Going private transaction (amended)
5 Jan 24
SC 13E3
Going private transaction
27 Nov 23
Latest ownership filings
SC 13D/A
Vivo Capital IX, LLC
2 Apr 24
SC 13D/A
ALEXANDRIA REAL ESTATE EQUITIES, INC.
1 Apr 24
SC 13D/A
Wang Sizhen
29 Mar 24
SC 13D/A
Tianjin Kangyue Business Management Partnership (Limited Partnership)
29 Mar 24
SC 13D
Wealth Strategy Group Ltd
24 Oct 23
SC 13D
ALEXANDRIA REAL ESTATE EQUITIES, INC.
23 Oct 23
SC 13D
Wang Sizhen
20 Oct 23
SC 13D
Tianjin Genetron Jun'an Business Management Partnership (Limited Partnership)
20 Oct 23
SC 13D
Tianjin Kangyue Business Management Partnership (Limited Partnership)
20 Oct 23
SC 13D
Vivo Capital IX, LLC
19 Oct 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 21 |
Opened positions | 3 |
Closed positions | 4 |
Increased positions | 1 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 9.47 bn |
Total shares | 221.11 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Wang Sizhen | 75.47 mm | $0.00 |
Tianjin Kangyue Business Management Partnership | 57.82 mm | $352.73 mm |
Vivo Capital IX | 28.57 mm | $0.00 |
Tianjin Genetron Jun'an Business Management Partnership | 26.08 mm | $159.11 mm |
Wealth Strategy | 23.40 mm | $327.62 mm |
Vivo Capital | 8.12 mm | $7.56 bn |
Baker Bros. Advisors | 455.31 k | $423.48 mm |
Yong Rong | 322.08 k | $300.00 k |
Robeco Institutional Asset Management B.V. | 272.40 k | $253.36 mm |
Hudson Bay Capital Management | 253.90 k | $236.15 mm |